Phase I/II Study of CAMPATH in Patients With Relapsing or Refractory Non-Hodgkin's Lymphoma
This study is being conducted in 2 parts with the primary objective of part 1 being to
determine the maximum tolerated dose (MTD) of CAMPATH (alemtuzumab, MABCAMPATH, CAMPATH)
administered intravenously (IV) once a week as treatment for relapsing or refractory
non-Hodgkin's lymphoma (NHL). The primary objective of part 2 is to determine the overall
response rate (complete response, CR/unconfirmed , plus partial response) of weekly IV
CAMPATH in the treatment of relapsing or refractory NHL. This is a Phase I/II study,
open-label, multicenter study to evaluate the efficacy and safety of weekly IV CAMPATH as
therapy for patients with relapsing or refractory non-Hodgkin's lymphoma.
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Medical Monitor
Study Director
Genzyme
United States: Food and Drug Administration
CAM.NHL232
NCT00051701
December 2002
June 2005
Name | Location |
---|---|
Alexandria, Minnesota 56308 | |
Columbia, Missouri 65203 | |
Cleveland, Ohio 44195 | |
Austin, Texas 78705 | |
Seattle, Washington 98195 | |
Kansas City, Kansas 66160 | |
Albuquerque, New Mexico 87131-5636 | |
Denver, Colorado | |
Indianapolis, Indiana | |
Tulsa, Oklahoma |